Semete, BKalombo, LonjiKatata, LChelule, PBooysen, LLemmer, YolandyNaidoo, SaloshneeRamalapa, BHayeshi, RSwai, HS2012-12-052012-12-052012-03Semete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., Naidoo, S., Ramalapa, B., Hayeshi, R. and Swai, H.S. 2012. Potential of improving the treatment of tuberculosis through nanomedicine. Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-3301542-1406http://www.tandfonline.com/doi/abs/10.1080/15421406.2012.635531http://hdl.handle.net/10204/6396Copyright: 2012 Taylor & Francis. This is the pre print version of the work. The definitive version is published in the journal of Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-330.Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200–300 nm were synthesized, with a drug encapsulation efficiency of 50–65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment.enDrug releaseNanomedicinePLGA nanoparticlesTuberculosisArticleSemete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., ... Swai, H. (2012). Potential of improving the treatment of tuberculosis through nanomedicine. http://hdl.handle.net/10204/6396Semete, B, Lonji Kalombo, L Katata, P Chelule, L Booysen, Yolandy Lemmer, Saloshnee Naidoo, B Ramalapa, R Hayeshi, and HS Swai "Potential of improving the treatment of tuberculosis through nanomedicine." (2012) http://hdl.handle.net/10204/6396Semete B, Kalombo L, Katata L, Chelule P, Booysen L, Lemmer Y, et al. Potential of improving the treatment of tuberculosis through nanomedicine. 2012; http://hdl.handle.net/10204/6396.TY - Article AU - Semete, B AU - Kalombo, Lonji AU - Katata, L AU - Chelule, P AU - Booysen, L AU - Lemmer, Yolandy AU - Naidoo, Saloshnee AU - Ramalapa, B AU - Hayeshi, R AU - Swai, HS AB - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200–300 nm were synthesized, with a drug encapsulation efficiency of 50–65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. DA - 2012-03 DB - ResearchSpace DP - CSIR KW - Drug release KW - Nanomedicine KW - PLGA nanoparticles KW - Tuberculosis LK - https://researchspace.csir.co.za PY - 2012 SM - 1542-1406 T1 - Potential of improving the treatment of tuberculosis through nanomedicine TI - Potential of improving the treatment of tuberculosis through nanomedicine UR - http://hdl.handle.net/10204/6396 ER -